Human medicines European public assessment report (EPAR): Ultibro Breezhaler, indacaterol,glycopyrronium bromide, Date of authorisation: 19/09/2013, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Armisarte (previously Pemetrexed Actavis), pemetrexed, Date of authorisation: 18/01/2016, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Ulunar Breezhaler, indacaterol,glycopyrronium bromide, Date of authorisation: 23/04/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Cresemba, isavuconazole, Date of authorisation: 15/10/2015, Revision: 21, Status: Authorised

Portfolio and technology meetings

Innovation Task Force (ITF) briefing meeting report

Innovation Task Force (ITF) briefing meeting request form

Risk minimisation measures (RMM)

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with new Addendum II to Module VI on masking of personal data in individual case safety reports submitted to EudraVigilance

Guideline on good pharmacovigilance practices (GVP) - Module VI Addendum II – Masking of personal data in individual case safety reports submitted to EudraVigilance